Pharmacokinetic modelling of DCE-MRI data allows characterisation of tumour response to anti-angiogenic therapies by estimating the volume transfer constant Ktrans and the plasma volume fraction Vp. This work assesses the impact on Ktrans and Vp of treatment changes in an early clinical trial cohort by comparing 4 models: Kety, extended Kety (with two lower limits on Vp), and a new model with Vp proportional to Ktrans. When Ktrans is the endpoint of interest, use of the Kety model is sufficient to depict cohort response. If Vp is also of interest, the new model improves the significance of Vp treatment effects.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords